Arbutus to Report Second Quarter 2020 Financial Results
July 29, 2020 08:00 ET
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., July 29, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with...
Arbutus to Present at Jefferies Virtual Healthcare Conference
May 27, 2020 08:00 ET
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., May 27, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company focused on developing a cure for people with chronic...
Arbutus Announces Single-Dose Week 12 Data in Chronic Hepatitis B Subjects with 60 mg AB-729 Demonstrating a Significant and Continuous Reduction in HBsAg
May 18, 2020 16:05 ET
|
Arbutus Biopharma Corporation
Mean 60 mg HBsAg reduction of 0.99 log10 IU/mL at week 12, with normal ALT and AST values throughout the follow-up period 90 mg single-dose and 60 mg multi-dose cohorts initiated with data expected...
Arbutus to Present at UBS Virtual Global Healthcare Conference
May 12, 2020 08:00 ET
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., May 12, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company focused on developing a cure for people with chronic...
Arbutus Reports First Quarter 2020 Financial Results, Provides Pipeline Update and Announces New Research Initiative to Identify Novel Antiviral Therapies for the Treatment of Coronavirus Infections
May 11, 2020 06:00 ET
|
Arbutus Biopharma Corporation
Arbutus remains on track to achieve its key 2020 objectives despite COVID-19 challenges Conference Call and Webcast Scheduled Today at 8:00 AM ET WARMINSTER, Pa., May 11, 2020 (GLOBE NEWSWIRE) --...
Arbutus to Report First Quarter 2020 Financial Results
May 04, 2020 08:00 ET
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., May 04, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it has scheduled its...
Arbutus Announces Positive Preliminary Phase 1a/1b Clinical Trial Results for AB-729, a Proprietary GalNAc Delivered RNAi Compound in Development for People Living with Chronic Hepatitis B
March 26, 2020 16:05 ET
|
Arbutus Biopharma Corporation
Positive single dose AB-729 data in chronic hepatitis B subjects supports further clinical development First multiple dose cohort results expected in second half of 2020 One or more additional...
Arbutus Reports Fourth Quarter and Year End 2019 Financial Results, Confirms 2020 Corporate Objectives and Provides Pipeline Update
March 05, 2020 07:30 ET
|
Arbutus Biopharma Corporation
Conference Call and Webcast Scheduled Today at 8:45 AM ET WARMINSTER, Pa., March 05, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a Hepatitis B Virus (HBV) therapeutic...
Arbutus to Report Fourth Quarter and Year-End 2019 Financial Results
February 27, 2020 08:00 ET
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it has scheduled its...
Arbutus Announces Decision to Discontinue AB-452 and to Pursue Development of a Next Generation HBV Specific Oral RNA-Destabilizer
February 10, 2020 08:00 ET
|
Arbutus Biopharma Corporation
Arbutus expects to announce AB-729 Preliminary Phase 1a/1b Data late Q12020 WARMINSTER, Pa., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), announced today its...